These data include general clinical information of glioma patients, such as gender, age, pathological type, and WHO classification of glioma, in addition to PRS (primary, recurring, secondary) type, IDH (isocitrate dehydrogenase) mutation and some data on the missing status of the 1p19q co-deletion. This evidence concerns the gene IDH3A and central nervous system cancer.